Neoadjuvant behandling øker andelen komplett patologisk respons ved HER2-positiv brystkreft
/ Bjørn Naume / Jan Andreasen
Trastuzumab and HER2 Targeted Cancer Treatment
/ Jan Trøst Jørgensen
DESTINY-Breast03 Study: Trastuzumab Deruxtecan versus Trastuzumab Emtansine
/ Giuseppe Curigliano








